Triple-Pill Therapy Reduces Recurrent Stroke Risk After Intracerebral Hemorrhage

A low-dose combination of telmisartan, amlodipine, and indapamide lowered systolic blood pressure and major cardiovascular events.

For Doctors in a Hurry

Clinicians lack evidence on whether adding a low-dose triple antihypertensive pill to standard care prevents recurrent stroke after intracerebral hemorrhage.
The researchers conducted a randomized trial of 1670 stable patients with a history of intracerebral hemorrhage and systolic blood pressure elevation.
The triple-pill group showed a 39 percent lower risk of recurrent stroke compared to placebo over 2.5 years (hazard ratio 0.61).
The authors concluded that this triple-pill regimen effectively reduces recurrent stroke and major cardiovascular events in this high-risk patient population.
Physicians should weigh the 13.6 percent rate of treatment discontinuation due to adverse events against the observed reduction in stroke risk.

Secondary Prevention Strategies After Intracerebral Hemorrhage

Secondary prevention after intracerebral hemorrhage is a significant clinical hurdle, as these patients remain at high risk for both recurrent bleeding and ischemic events [1]. While blood pressure reduction is the primary evidence-based intervention for stroke prevention, the most effective pharmacological strategy for maintaining targets in this population remains unclear [2]. Clinicians must balance the benefits of intensive therapy against the risk of adverse events, particularly in patients with small vessel disease or cerebral microbleeds [3, 4]. Despite the known benefits of antihypertensive therapy, many patients fail to reach goal pressures, suggesting a need for more effective delivery methods for secondary prevention [5]. A recent multinational trial now evaluates whether a specific combination strategy can improve these clinical outcomes.

Trial Design and Low-Dose Combination Regimen

The TRIDENT trial was a multinational, double-blind, randomized, placebo-controlled study that evaluated a fixed-dose combination strategy for secondary stroke prevention. The study enrolled 1670 patients with a mean age of 58 years who had a documented history of intracerebral hemorrhage. Eligibility required patients to be clinically stable with a baseline systolic blood pressure between 130 and 160 mm Hg, a range that captures many hypertensive or pre-hypertensive outpatients seen in routine clinical practice. Before randomization, the researchers utilized a 2-week active run-in phase (a period where all participants take the study medication to ensure they can tolerate the drugs and follow the protocol) involving a once-daily triple pill. This pill combined low doses of three antihypertensive classes: the angiotensin receptor blocker telmisartan at 20 mg, the calcium channel blocker amlodipine at 2.5 mg, and the thiazide-like diuretic indapamide at 1.25 mg. Following this phase, 833 patients continued the triple-pill regimen while 837 received a matching placebo, with the study receiving funding from the National Health and Medical Research Council of Australia and the Brazilian Ministry of Health.

Impact on Recurrent Stroke and Cardiovascular Events

The primary outcome of the TRIDENT trial was the occurrence of the first recurrent stroke, a metric that directly informs long-term management strategies for hemorrhage survivors. Over a median follow-up of 2.5 years, the researchers found that recurrent stroke occurred in 38 patients (4.6%) in the triple-pill group compared to 62 patients (7.4%) in the placebo group. This resulted in a hazard ratio of 0.61 (95% confidence interval [CI], 0.41 to 0.92; P = 0.02), which represents a 39 percent reduction in the relative risk of a subsequent stroke when the triple-pill regimen is added to standard care. The study also tracked major cardiovascular events, finding an incidence of 6.6% in the triple-pill group versus 9.8% in the placebo group (P = 0.04). These data suggest that the intensified blood pressure management provided by a low-dose combination approach offers broad vascular protection beyond the prevention of cerebrovascular events alone. For the practicing clinician, these findings indicate that a simplified, multi-drug strategy may be more effective than traditional titration for reducing the cumulative burden of vascular disease in this high-risk cohort.

Blood Pressure Control and Renal Safety Considerations

Consistent blood pressure control is the cornerstone of post-hemorrhage care, and the TRIDENT trial demonstrated that the triple-pill regimen achieved superior pressure reduction compared to standard care. The mean systolic blood pressure during follow-up was 127 mm Hg in the triple-pill group compared to 138 mm Hg in the placebo group, an 11 mm Hg difference that likely drove the observed reduction in recurrent events. Regarding safety, serious adverse events occurred in 23.2% of the triple-pill group and 26.0% of the placebo group, indicating that the more intensive regimen did not increase the overall rate of life-threatening complications. However, early discontinuation of the trial regimen due to an adverse event was higher in the triple-pill group (13.6%) than in the placebo group (6.0%). The most frequent cause for discontinuation was an increase of 20% or more in the serum creatinine level, a common marker of altered renal hemodynamics (the way blood flows through the kidneys) when initiating multiple antihypertensive agents. This finding suggests that while the triple-pill approach is effective, clinicians should implement routine monitoring of renal function and electrolytes when adding this combination to a patient's existing regimen.

Study Info

Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage

The Trident Research Group

Journal New England Journal of Medicine

Published April 22, 2026